3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
4
Tumor-Agnostic
3
CNS
3
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Conditions
Sarcoma
4
Melanoma
4
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Osteosarcoma
2
Gliosarcoma
2
Glioblastoma
2
Carcinoma, Merkel Cell
2
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma, T-Cell, Cutaneous
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Chondrosarcoma
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Basal Cell
1
Bone Neoplasms
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
17
pembrolizumab
12
Doxorubicin
10
fludarabine
7
Irinotecan
7
Blood Specimen Collection
7
Temozolomide
6
Gemcitabine
6
Etoposide
6
Radiotherapy
5
Ifosfamide
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
tecogalan
4
cemiplimab
4
Vincristine
4
Trabectedin
4
Paclitaxel
4
Nivolumab
4
Filgrastim
4
Drug Therapy
4
Dexamethasone
4
Bevacizumab
4
pazopanib
3
olaparib
3
nilotinib
3
dostarlimab
3
aflibercept
3
Therapeutics
3
Taxes
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
poly ICLC
×
Sarcoma
×
Clear all
NCT02423863
2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2
Completed
26 enrolled